IRIS Institutional Research Information System - OPENBS Open Archive UniBS

The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Nodari S
Membro del Collaboration Group
2020-01-01

Abstract

The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.
2020
2020
NEW ENGLAND JOURNAL OF MEDICINE
2-s2.0-85083438658
WOS:000535944700017
Inglese
382
20
1883-1893
1893
32222134
Administration, Oral; Aged; Cardiovascular Diseases; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Hypotension; Incidence; Male; Middle Aged; Pyrimidines; Soluble Guanylyl Cyclase; Stroke Volume; Syncope; Ventricular Dysfunction, Left
sì
17
info:eu-repo/semantics/article
262
Armstrong, Paul W; Pieske, Burkert; Anstrom, Kevin J; Ezekowitz, Justin; Hernandez, Adrian F; Butler, Javed; Lam, Carolyn S P; Ponikowski, Piotr; Voor...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/538684
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 523
  • Scopus 1208
  • ???jsp.display-item.citation.isi??? 1048
social impact